THE DEAL, AT A GLANCE
From the announcementOblenio Bio
01What it doesLed by Samantha Truex Oblenio Bio is developing a broad immune reset as a transformative therapy for refractory autoimmune diseases through its T-cell activator LBL-051.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗02Who is involvedBacked by Pfizer Ventures, new investors Deep Track Capital, GV, Aditum BioFrom the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗03What happenedOblenio Bio raised $62M Series B, announced 2026-06-25From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗04Why it mattersOblenio Bio is using its $62M Series B to move LBL-051 into initial clinical development for refractory autoimmune diseases.From the announcement
Summarized from the deal record's source announcement; not yet independently reviewed.
Read the announcement ↗Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗
Oblenio Bio · Financing Record
Explore source-linked visual explanations for Oblenio Bio. Unsupported claims are withheld while source review continues.
Record 6731 · Recorded date: 2026-06-25
Explore company records →